Rebeca T. King

Rebeca T. King

Auto-generated profile, based on publicly available information

Rebeca T. King

Department of Biochemistry and Molecular Biophysics, Columbia University, New York, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Cell
Verified
Journal Article
Closed access
MZMichael V. Zuccaro
Michael V. Zuccaro
JXJia Xu
Jia Xu
CMCarl Mitchell
Carl Mitchell
DMDiego Marin
Diego Marin
RZRaymond Zimmerman
Raymond Zimmerman
DEDieter Egli
Dieter Egli

29 March 2023 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
GLGeorge D. Lampe
George D. Lampe
RKRebeca T. King
Rebeca T. King
THTyler S. Halpin-Healy
Tyler S. Halpin-Healy
SKSanne E. Klompe
Sanne E. Klompe
MHMarcus I. Hogan
Marcus I. Hogan
SSSamuel H. Sternberg
Samuel H. Sternberg

15 May 2025 in Science
Verified
Journal Article
Open access
IWIsaac P. Witte
Isaac P. Witte
GLGeorge D. Lampe
George D. Lampe
SESimon Eitzinger
Simon Eitzinger
SMShannon M. Miller
Shannon M. Miller
KBKiara N. Berríos
Kiara N. Berríos
DLDavid R. Liu
David R. Liu
Programmable gene integration in human cells has the potential to enable mutation-agnostic treatments for loss-of-function genetic diseases and facilitate many applications in the life sciences. CRISPR-associated transposases (CASTs) catalyze RNA-guided DNA integration but thus far demonstrate minimal activity in human cells. Using phage-assisted continuous evolution (PACE), we generated CAST variants with >200-fold average improved integration activity. The evolved CAST system (evoCAST) achieves ~10 to 30% integration efficiencies of kilobase-size DNA cargoes in human cells across 14 tested genomic target sites, including safe harbor loci, sites used for immunotherapy, and genes implicated in loss-of-function diseases, with undetected indels and low levels of off-target integration. Collectively, our findings establish a platform for the laboratory evolution of CASTs and advance a versatile system for programmable gene integration in living systems.

18 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
GLGeorge D. Lampe
George D. Lampe
RKRebeca T. King
Rebeca T. King
THTyler S. Halpin-Healy
Tyler S. Halpin-Healy
SKSanne E. Klompe
Sanne E. Klompe
MHMarcus I. Hogan
Marcus I. Hogan
SSSamuel H. Sternberg
Samuel H. Sternberg
Traditional genome-editing reagents such as CRISPR-Cas9 achieve targeted DNA modification by introducing double-strand breaks (DSBs), thereby stimulating localized DNA repair by endogenous cellular repair factors. While highly effective at generating heterogenous knockout mutations, this approach suffers from undesirable byproducts and an inability to control product purity. Here we develop a system in human cells for programmable, DSB-free DNA integration using Type I CRISPR-associated transposons (CASTs). To adapt our previously described CAST systems, we optimized DNA targeting by the QCascade complex through a comprehensive assessment of protein design, and we developed potent transcriptional activators by exploiting the multi-valent recruitment of the AAA+ ATPase, TnsC, to genomic sites targeted by QCascade. After initial detection of plasmid-based transposition, we screened 15 homologous CAST systems from a wide range of bacterial hosts, identified a CAST homolog from Pseudoalteromonas that exhibited improved activity, and increased integration efficiencies through parameter optimization. We further discovered that bacterial ClpX enhances genomic integration by multiple orders of magnitude, and we propose that this critical accessory factor functions to drive active disassembly of the post-transposition CAST complex, akin to its demonstrated role in Mu transposition. Our work highlights the ability to functionally reconstitute complex, multi-component machineries in human cells, and establishes a strong foundation to realize the full potential of CRISPR-associated transposons for human genome engineering.

7 September 2026 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
GLGeorge D. Lampe
George D. Lampe
RKRebeca T. King
Rebeca T. King
SSSamuel H. Sternberg
Samuel H. Sternberg